Position in NVAX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$2,778
+$2,776 QoQ
Shares Held
295
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#218
of 263 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BESSEMER GROUP INC holds $406,568,683 across 93 Biotechnology names. NVAX ranks #72 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
267,779 | $248,437,315 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
141,449 | $44,708,085 | |
| 3 | MAZE |
Maze Therapeutics, Inc.
|
481,790 | $14,376,613 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
354,206 | $11,072,479 | |
| 5 | RLAY |
Relay Therapeutics, Inc.
|
457,869 | $8,566,728 | |
| 6 | KRYS |
Krystal Biotech, Inc.
|
20,285 | $7,539,324 | |
| 7 | NRIX |
Nurix Therapeutics, Inc.
|
306,003 | $7,423,632 | |
| 8 | TGTX |
Tg Therapeutics, Inc.
|
132,555 | $7,280,868 |
All Filings in NVAX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,778 | 295 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $2 | 295 | Shares | Defined | 2026-05-06 | |
| 2025-12-31 | $2,170 | 323 | Shares | Defined | 2026-02-05 | |
| 2025-09-30 | $242 | 28 | Shares | Defined | 2025-11-05 | |
| 2025-06-30 | $1 | 95 | Shares | Defined | 2025-08-01 | |
| 2025-03-31 | $1 | 95 | Shares | Defined | 2025-04-23 | |
| 2024-09-30 | $1 | 70 | Shares | Defined | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||